Range Financial Group LLC Acquires Shares of 238 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Range Financial Group LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 238 shares of the biopharmaceutical company’s stock, valued at approximately $229,000.

A number of other large investors have also recently made changes to their positions in REGN. Traynor Capital Management Inc. grew its stake in Regeneron Pharmaceuticals by 4.7% in the 1st quarter. Traynor Capital Management Inc. now owns 19,746 shares of the biopharmaceutical company’s stock worth $19,005,000 after acquiring an additional 878 shares in the last quarter. Northwest Investment Counselors LLC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth $177,000. Ballentine Partners LLC increased its holdings in shares of Regeneron Pharmaceuticals by 37.7% during the first quarter. Ballentine Partners LLC now owns 1,040 shares of the biopharmaceutical company’s stock valued at $1,001,000 after acquiring an additional 285 shares in the last quarter. International Assets Investment Management LLC increased its stake in Regeneron Pharmaceuticals by 9.4% during the 1st quarter. International Assets Investment Management LLC now owns 736 shares of the biopharmaceutical company’s stock valued at $713,000 after purchasing an additional 63 shares in the last quarter. Finally, Gulf International Bank UK Ltd increased its position in shares of Regeneron Pharmaceuticals by 0.5% in the 1st quarter. Gulf International Bank UK Ltd now owns 8,907 shares of the biopharmaceutical company’s stock valued at $8,572,000 after acquiring an additional 43 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 1.0 %

NASDAQ:REGN opened at $1,063.89 on Tuesday. The stock has a 50-day simple moving average of $971.15 and a 200-day simple moving average of $945.80. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The stock has a market cap of $117.23 billion, a P/E ratio of 31.43, a P/E/G ratio of 2.18 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $1,068.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The firm had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

REGN has been the subject of a number of recent research reports. Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target for the company. Royal Bank of Canada restated an “outperform” rating and set a $1,229.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday. Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price on the stock. UBS Group boosted their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Monday, June 17th. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $998.09.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of the stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the completion of the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Leonard S. Schleifer sold 22,830 shares of the stock in a transaction on Friday, May 17th. The stock was sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the transaction, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The disclosure for this sale can be found here. Insiders sold a total of 61,215 shares of company stock worth $60,414,782 in the last 90 days. 7.48% of the stock is owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.